22nd Oct 2015 10:32
LONDON (Alliance News) - Eli Lilly and Co and AstraZeneca PLC announced an extension to their existing immuno-oncology collaboration exploring combination therapies for the treatment of patients with solid tumors. Lilly and AstraZeneca will evaluate the safety and efficacy of a range of additional combinations across the companies' complementary portfolios.
AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab, will be combined with Lilly molecules that target the immune system.
Richard Gaynor, senior vice president, product development and medical affairs for Lilly Oncology, said, "The expansion of Lilly's research partnership with AstraZeneca will explore the far-reaching potential of combining novel targeted therapies. Our respective pipelines afford multiple targeted options to create innovative combinations in immuno-oncology and beyond, that we hope will lead to future cancer treatment options."
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca